Also trades as: RCE.AX (ASX) · $vol 0M
RECEF OTC
Recce Pharmaceuticals Ltd
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -63.3%
$0.22
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$369K
+87.4% ▲
Operating Income
-$24M
-4.9% ▼
Net Income
-$16M
+27.6% ▲
EPS (Diluted)
$-0.05
+40.7% ▲
EBITDA
-$24M
-16.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $3M | $4M | $7M | $8M | $0 |
| YoY Growth | +88.4% | +41.5% | +56.9% | +9.6% | -100.0% |
| Cost of Revenue | $188K | $217K | $7M | $10M | $369K |
| Gross Profit | $3M | $4M | -$367K | -$3M | -$369K |
| Gross Margin | 93.9% | 95.0% | -5.4% | -39.1% | — |
| R&D Expenses | $6M | $7M | $0 | $10M | $0 |
| SG&A Expenses | $3M | $5M | $7M | $10M | $24M |
| Operating Expenses | $14M | $17M | $14M | $20M | $24M |
| Operating Income | -$14M | -$17M | -$22M | -$23M | -$24M |
| Operating Margin | -458.7% | -396.9% | -321.9% | -304.7% | — |
| Interest Expense | $12K | $183K | $847K | $0 | $2M |
| Income Before Tax | -$14M | -$17M | -$23M | -$21M | -$25M |
| Tax Expense | -$3M | -$4M | -$5M | $0 | -$9M |
| Net Income | -$11M | -$13M | -$18M | -$21M | -$16M |
| Net Margin | -356.1% | -299.6% | -257.8% | -285.4% | — |
| EPS (Diluted) | $-0.06 | $-0.07 | $-0.10 | $-0.09 | $-0.05 |
| EBITDA | -$11M | -$17M | -$21M | -$20M | -$24M |
| Shares Outstanding | 176M | 176M | 177M | 237M | 289M |